[go: up one dir, main page]

MX2018006390A - Composiciones y metodos para tratar accidente cerebrovascular isquemico. - Google Patents

Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Info

Publication number
MX2018006390A
MX2018006390A MX2018006390A MX2018006390A MX2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A
Authority
MX
Mexico
Prior art keywords
methods
ischemic stroke
compositions
formula
treating ischemic
Prior art date
Application number
MX2018006390A
Other languages
English (en)
Other versions
MX390748B (es
Inventor
Elmaleh David
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of MX2018006390A publication Critical patent/MX2018006390A/es
Publication of MX390748B publication Critical patent/MX390748B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención está dirigida a métodos de tratamiento de un accidente cerebrovascular isquémico administrando una cantidad terapéuticamente eficaz de al menos un compuesto de Fórmula I o Fórmula II a un sujeto que lo necesita, donde el compuesto tiene la Fórmula I o Fórmula II o una sal o éster de (I) o (II); donde X es OH, alcoxilo C1-C6, 18F o 19F; Y y Z se seleccionan independientemente de alquilo C1-C6, alcoxilo C1-C6, halógeno, amina C1-C6 sustituida o no sustituida, 18F, 19F o H; y n es 1, 2 o 3.
MX2018006390A 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico. MX390748B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
MX2018006390A true MX2018006390A (es) 2019-02-14
MX390748B MX390748B (es) 2025-03-21

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006390A MX390748B (es) 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Country Status (9)

Country Link
US (2) US20180344682A1 (es)
EP (1) EP3380095B1 (es)
JP (1) JP2018538273A (es)
KR (1) KR20180081812A (es)
CN (1) CN108472275A (es)
AU (1) AU2016359674A1 (es)
CA (1) CA3005909A1 (es)
MX (1) MX390748B (es)
WO (1) WO2017091644A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2018045217A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
EP3720429A4 (en) * 2017-12-04 2021-09-15 The General Hospital Corporation COMPOSITIONS BASED ON CROMOGLICIC ACID AND RELATED PROCESSES
US20210059977A1 (en) * 2018-04-09 2021-03-04 The General Hospital Corporation Combination therapies for the treatment of amyotrophic lateral sclerosis and related disorders
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
RU2428987C2 (ru) * 2004-08-30 2011-09-20 Сео Хонг Ю Нейрозащитное действие растворимой урсодезоксихолевой кислоты в моделях фокальной ишемии
CN105061376A (zh) * 2009-01-29 2015-11-18 通用医疗公司 色甘酸衍生物以及成像和治疗的相关方法
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
RU2015132478A (ru) * 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
WO2010104973A1 (en) * 2009-03-11 2010-09-16 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
CN104869993B (zh) * 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN106456595A (zh) * 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于系统性病症的肥大细胞稳定剂治疗
WO2018045217A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Also Published As

Publication number Publication date
US20180344682A1 (en) 2018-12-06
EP3380095A1 (en) 2018-10-03
US20220125753A1 (en) 2022-04-28
EP3380095A4 (en) 2019-10-23
AU2016359674A1 (en) 2018-06-14
CN108472275A (zh) 2018-08-31
KR20180081812A (ko) 2018-07-17
EP3380095B1 (en) 2022-01-05
JP2018538273A (ja) 2018-12-27
MX390748B (es) 2025-03-21
CA3005909A1 (en) 2017-06-01
WO2017091644A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MX2018006390A (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
AR125320A2 (es) Compuesto cristalino, método de preparación y composición que lo comprende
EA201890522A1 (ru) Способ получения противогрибковых соединений
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
EA201691156A1 (ru) Пирролидиноновые гербициды
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
MY169495A (en) Pharmaceutical compositions
MX2017011821A (es) Silanos y composiciones curables que contienen dichos silanos como reticulantes.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
MX2020003020A (es) Compuestos de aminocarbonilcarbamato.
MX387483B (es) Preparación farmacéutica.
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
EA201690879A1 (ru) Новое триазолопиридиновое соединение
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
MX382175B (es) Composiciones de profármaco de monometilfumarato
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
EA202090040A1 (ru) Композиция для инъекции
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
MX2019000837A (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk?2.